Page last updated: 2024-10-28

lidocaine and Reperfusion Injury

lidocaine has been researched along with Reperfusion Injury in 46 studies

Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.

Reperfusion Injury: Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.

Research Excerpts

ExcerptRelevanceReference
"The primary aim of this study was to compare the effects of a small-dose infusion of 2 antioxidant agents, ketamine and lidocaine, on ischemia-reperfusion injury (IRI) in patients undergoing elective lower limb surgery."9.30The effects of ketamine and lidocaine on free radical production after tourniquet-induced ischemia-reperfusion injury in adults. ( Deyişli, C; Kıyıcı, A; Ökesli, S; Peker, K, 2019)
" This study aimed to investigate whether lidocaine relieves SCIRI via modulating myocardial infarction-associated transcript (MIAT)-mediated Notch1 downregulation."8.12Lidocaine relieves spinal cord ischemia-reperfusion injury via long non-coding RNA MIAT-mediated Notch1 downregulation. ( Hou, J; Li, H; Ma, J; Xue, C, 2022)
"To evaluate the effects of an intraperitoneal solution of methylene blue (MB), lidocaine and pentoxyphylline (PTX) on intestinal ischemic and reperfusion injury."7.83Direct intraperitoneal resuscitation with lidocaine, methylene blue and pentoxiphylline combination does not decreases inflammation after intestinal ischemia-reperfusion injury in rats. ( Cerri, S; Farca, AM; Gandini, M; Giusto, G; Iussich, S; Pregel, P; Tursi, M; Vercelli, C, 2016)
"To study the protective effects of lidocaine and nerve growth factor (NGF) pretreatment on cerebral ischemia/reperfusion (I/R) injury."7.76[A study of the protective effects of lidocaine and nerve growth factor pretreatment on cerebral ischemia/reperfusion injury in gerbils]. ( Wang, DF; Xie, JD, 2010)
"Data pertaining to breed; time lag to admission; clinical, clinicopathologic, and surgical findings; lidocaine treatment; and postoperative complications were assessed for association with outcome."7.74Evaluation of lidocaine treatment and risk factors for death associated with gastric dilatation and volvulus in dogs: 112 cases (1997-2005). ( Bdolah-Abram, T; Bruchim, Y; Buber, T; Epstein, A; Ranen, E; Saragusty, J, 2007)
"Our observations indicate that lidocaine reduces reperfusion injury and inhibits PMN adhesion and subsequent migration to the lung allograft."7.69Lidocaine reduces reperfusion injury and neutrophil migration in canine lung allografts. ( Ando, K; Cooper, JD; Patterson, GA; Schmid, RA; Tanaka, Y; Yamashita, M, 1996)
"Lidocaine has anti-inflammatory properties."5.62Effect of Intravenous Lidocaine on Inflammatory and Apoptotic Response of Ischemia-Reperfusion Injury in Pigs Undergoing Lung Resection Surgery. ( Carricondo, F; Cebollero, M; García-Aldao, U; Garutti, I; Martín-Albo, L; Ortega, J; Romera, A; Romero-Gómez, B; Simón, C; Vara, E; Zapatero, S, 2021)
"Lidocaine has proven anti-inflammatory activity in several tissues but its modulation of miRNAs has not been investigated."5.43Lidocaine Administration Controls MicroRNAs Alterations Observed After Lung Ischemia-Reperfusion Injury. ( Calvo, A; Casanova, J; García, C; Garutti, I; Marchal-Duval, E; Paredes, SD; Rancan, L; Rincón, D; Simón, C; Turrero, A; Vara, E, 2016)
"Lidocaine inhibited the increase in MDA level associated with IR injury while showing no influence over increases in number of neutrophils and tissue MPO level, and it elevated the flap survival rate."5.37The impact of lidocaine on flap survival following reperfusion injury. ( Canoz, O; Eskitascioglu, T; Gunay, GK; Karaci, S; Kılıc, E, 2011)
"The primary aim of this study was to compare the effects of a small-dose infusion of 2 antioxidant agents, ketamine and lidocaine, on ischemia-reperfusion injury (IRI) in patients undergoing elective lower limb surgery."5.30The effects of ketamine and lidocaine on free radical production after tourniquet-induced ischemia-reperfusion injury in adults. ( Deyişli, C; Kıyıcı, A; Ökesli, S; Peker, K, 2019)
" Riluzole, Lidocaine and Lamotrigine were given prior to renal ischemia only (IO) or IRI."4.12Pharmacological prevention of renal ischemia-reperfusion injury in a rat model. ( Deng, Y; Li, RW; Smith, PN; Weiss, S; Yang, YL, 2022)
" This study aimed to investigate whether lidocaine relieves SCIRI via modulating myocardial infarction-associated transcript (MIAT)-mediated Notch1 downregulation."4.12Lidocaine relieves spinal cord ischemia-reperfusion injury via long non-coding RNA MIAT-mediated Notch1 downregulation. ( Hou, J; Li, H; Ma, J; Xue, C, 2022)
" The lower cell counts of caspase- and calprotectin-positive cells in group X may indicate a beneficial effect of xylazine on ischaemia/reperfusion injury."4.02Preconditioning with lidocaine and xylazine in experimental equine jejunal ischaemia. ( Kästner, S; König, K; Neudeck, S; Pfarrer, C; Rohn, K; Twele, L; Verhaar, N, 2021)
" The aim of our research was to compare molsidomine, SIN-1, SIN-1A, and lidocaine influence on arrhythmias and hemodynamic parameters in 2 experimental models in rats."3.85New approach to molsidomine active metabolites coming from the results of 2 models of experimental cardiology. ( Krzemiński, TF; Mitręga, KA; Porc, M; Żorniak, M, 2017)
"To evaluate the effects of an intraperitoneal solution of methylene blue (MB), lidocaine and pentoxyphylline (PTX) on intestinal ischemic and reperfusion injury."3.83Direct intraperitoneal resuscitation with lidocaine, methylene blue and pentoxiphylline combination does not decreases inflammation after intestinal ischemia-reperfusion injury in rats. ( Cerri, S; Farca, AM; Gandini, M; Giusto, G; Iussich, S; Pregel, P; Tursi, M; Vercelli, C, 2016)
"In vivo administration of lidocaine allowed maintenance of contractile performance after an ischemia and reperfusion injury."3.77Effects of in vivo lidocaine administration at the time of ischemia and reperfusion on in vitro contractility of equine jejunal smooth muscle. ( Feige, K; Geburek, F; Guschlbauer, M; Hoppe, S; Hopster, K; Huber, K; Pröpsting, MJ, 2011)
"To study the protective effects of lidocaine and nerve growth factor (NGF) pretreatment on cerebral ischemia/reperfusion (I/R) injury."3.76[A study of the protective effects of lidocaine and nerve growth factor pretreatment on cerebral ischemia/reperfusion injury in gerbils]. ( Wang, DF; Xie, JD, 2010)
" The present study was designed to examine the effects of hypoxia/reperfusion on the disposition of glutamate and propranolol in the rat isolated perfused liver."3.74Effects of hypoxia/reperfusion injury on drug disposition in the rat isolated perfused liver. ( Arab, HA; Cheung, K; Hickman, PE; Kadkhodaee, M; Potter, JM; Roberts, MS, 2007)
"Data pertaining to breed; time lag to admission; clinical, clinicopathologic, and surgical findings; lidocaine treatment; and postoperative complications were assessed for association with outcome."3.74Evaluation of lidocaine treatment and risk factors for death associated with gastric dilatation and volvulus in dogs: 112 cases (1997-2005). ( Bdolah-Abram, T; Bruchim, Y; Buber, T; Epstein, A; Ranen, E; Saragusty, J, 2007)
"Lidocaine and thiopental improve recovery when administrated during hypoxia and ischemia; however, the effect of pre- or postinsult treatment alone is unknown."3.73Pre- or postinsult administration of lidocaine or thiopental attenuates cell death in rat hippocampal slice cultures caused by oxygen-glucose deprivation. ( Bergold, PJ; Cao, H; Cottrell, JE; Kass, IS, 2005)
"Oxygen radical production is thought to be fundamental to the pathogenesis of post-ischaemic reperfusion injury which is routinely managed with lidocaine."3.70Dose-dependent suppression of the neutrophil respiratory burst by lidocaine. ( Hyvönen, PM; Kowolik, MJ, 1998)
") reduced or completely abolished the ventricular fibrillation (VF) induced by reperfusion after 5 min of regional ischemia, while lidocaine, a class I antiarrhythmic agent, showed less effect against VF as compared with FR168888."3.70Protective effect of FR168888, a new Na+/H+ exchange inhibitor, on ischemia and reperfusion-induced arrhythmia and myocardial infarction in rats: in comparison with other cardioprotective compounds. ( Goto, T; Maeda, K; Ohara, F; Ohkubo, K; Ozaki, T; Seki, J; Sugimoto, T; Yamamoto, N, 1999)
"Antiarrhythmic drugs, such as lidocaine, quinidine, and procainamide, have been shown to be effective against postischemic reperfusion injury in isolated rat lungs."3.69Amelioration of postischemic reperfusion injury by antiarrhythmic drugs in isolated perfused rat lung. ( Das, KC; Misra, HP, 1994)
"Our observations indicate that lidocaine reduces reperfusion injury and inhibits PMN adhesion and subsequent migration to the lung allograft."3.69Lidocaine reduces reperfusion injury and neutrophil migration in canine lung allografts. ( Ando, K; Cooper, JD; Patterson, GA; Schmid, RA; Tanaka, Y; Yamashita, M, 1996)
"Lidocaine has anti-inflammatory properties."1.62Effect of Intravenous Lidocaine on Inflammatory and Apoptotic Response of Ischemia-Reperfusion Injury in Pigs Undergoing Lung Resection Surgery. ( Carricondo, F; Cebollero, M; García-Aldao, U; Garutti, I; Martín-Albo, L; Ortega, J; Romera, A; Romero-Gómez, B; Simón, C; Vara, E; Zapatero, S, 2021)
"Lidocaine has a proven anti-inflammatory activity in several tissues but its modulation of glycocalyx has not been investigated."1.48Glycocalyx Degradation after Pulmonary Transplantation Surgery. ( Aymonnier, K; Casanova, J; Garutti, I; Muñoz, C; Rancan, L; Sánchez Pedrosa, G; Shahani, PM; Simón, C; Vara, E, 2018)
"Lidocaine has proven anti-inflammatory activity in several tissues but its modulation of miRNAs has not been investigated."1.43Lidocaine Administration Controls MicroRNAs Alterations Observed After Lung Ischemia-Reperfusion Injury. ( Calvo, A; Casanova, J; García, C; Garutti, I; Marchal-Duval, E; Paredes, SD; Rancan, L; Rincón, D; Simón, C; Turrero, A; Vara, E, 2016)
"Lidocaine inhibited the increase in MDA level associated with IR injury while showing no influence over increases in number of neutrophils and tissue MPO level, and it elevated the flap survival rate."1.37The impact of lidocaine on flap survival following reperfusion injury. ( Canoz, O; Eskitascioglu, T; Gunay, GK; Karaci, S; Kılıc, E, 2011)
" The protection of mitochondrial functions was almost complete at a dosage of 10 mg/kg/day during normothermic ischemia and 10 microg/ml in the preservation liquid during hypothermic ischemia."1.35Protection of cellular and mitochondrial functions against liver ischemia by N-benzyl-N'-(2-hydroxy-3,4-dimethoxybenzyl)-piperazine (BHDP), a sigma1 ligand. ( Ferchichi, H; Klouz, A; Kourda, N; Lakhal, M; Morin, D; Ouanes, L; Saïd, DB; Tillement, JP, 2008)
"Lidocaine and phenol were injected into the sciatic nerves of the rats in Groups 1 and 2, respectively."1.32Free radical-induced damage in experimental peripheral nerve injection injury. ( Apan, A; Kisa, U; Saray, A, 2003)
"Lidocaine has actions potentially of benefit during ischaemia-reperfusion."1.32The effect of lidocaine on neutrophil CD11b/CD18 and endothelial ICAM-1 expression and IL-1beta concentrations induced by hypoxia-reoxygenation. ( Harmon, D; Lan, W; Redmond, P; Shorten, G; Wang, JH, 2004)
"Paraplegia secondary to spinal cord ischemia is a devastating complication in operations on the descending and thoracoabdominal aorta."1.31Regional lidocaine infusion reduces postischemic spinal cord injury in rabbits. ( Apaydin, AZ; Büket, S, 2001)

Research

Studies (46)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's8 (17.39)18.2507
2000's15 (32.61)29.6817
2010's16 (34.78)24.3611
2020's7 (15.22)2.80

Authors

AuthorsStudies
Deng, Y1
Li, RW1
Yang, YL1
Weiss, S1
Smith, PN1
Franko, JJ1
Vu, MM1
Parsons, ME1
Conner, JR1
Lammers, DT1
Ieronimakis, N1
Reynolds, GD1
Eckert, MJ1
Bingham, JR1
Hou, J1
Li, H1
Xue, C1
Ma, J1
Verhaar, N1
Pfarrer, C1
Neudeck, S1
König, K1
Rohn, K1
Twele, L1
Kästner, S1
Del Rio, M1
Lopez-Cabrera, P1
Malagón-López, P1
Del Caño-Aldonza, MC1
Castello, JR1
Provencio, M1
Romera, A1
Cebollero, M1
Romero-Gómez, B1
Carricondo, F1
Zapatero, S1
García-Aldao, U1
Martín-Albo, L1
Ortega, J1
Vara, E3
Garutti, I3
Simón, C3
Conner, J1
Lammers, D1
Holtestaul, T1
Jones, I1
Kuckelman, J1
Letson, H1
Dobson, G1
Eckert, M1
Bingham, J1
Rancan, L2
Sánchez Pedrosa, G1
Aymonnier, K1
Shahani, PM1
Casanova, J2
Muñoz, C1
Peker, K1
Ökesli, S1
Kıyıcı, A2
Deyişli, C1
Granfeldt, A3
Shi, W1
Schmarkey, SL1
Jiang, R1
Bone, CC1
Cline, JM1
Wogensen, L1
Dobson, GP2
Tønnesen, E2
Vinten-Johansen, J1
Tappenbeck, K2
Hoppe, S4
Reichert, C1
Feige, K4
Huber, K4
Nielsen, TK1
Hvas, CL1
Onoglu, R1
Narin, C1
Sarkilar, G1
Hacibeyoglu, G1
Baba, F1
Sarigul, A1
Gandini, M1
Cerri, S1
Pregel, P1
Giusto, G1
Vercelli, C1
Iussich, S1
Tursi, M1
Farca, AM1
Marchal-Duval, E1
Paredes, SD1
Calvo, A1
García, C1
Rincón, D1
Turrero, A1
Żorniak, M1
Mitręga, KA1
Porc, M1
Krzemiński, TF1
Eskitascioglu, T1
Karaci, S1
Canoz, O1
Kılıc, E1
Gunay, GK1
Guschlbauer, M2
Geburek, F2
Xie, JD1
Wang, DF1
Tasi, WC1
Petersen-Jones, SM1
Huang, PY1
Lin, CT1
Hopster, K2
Pröpsting, MJ1
Kietzmann, M1
Saray, A1
Apan, A1
Kisa, U1
Lee, HT1
Krichevsky, IE1
Xu, H1
Ota-Setlik, A1
D'Agati, VD1
Emala, CW1
Chen, MY1
Li, CH1
Huang, ZQ1
Liu, JC1
Zhou, NX1
Huang, XQ1
Wang, YS1
Lan, W2
Harmon, D2
Wang, JH2
Ghori, K1
Shorten, G2
Redmond, P2
Eghtesadi-Araghi, P1
Marashi, SM1
Cao, H1
Kass, IS2
Cottrell, JE2
Bergold, PJ1
Arab, HA1
Cheung, K1
Hickman, PE1
Potter, JM1
Kadkhodaee, M1
Roberts, MS1
Buber, T1
Saragusty, J1
Ranen, E1
Epstein, A1
Bdolah-Abram, T1
Bruchim, Y1
Klouz, A1
Saïd, DB1
Ferchichi, H1
Kourda, N1
Ouanes, L1
Lakhal, M1
Tillement, JP1
Morin, D1
Cook, VL1
Blikslager, AT1
Walsh, RM1
Tanaka, J1
Malchesky, PS1
Sato, N1
Nakayama, S1
Vogt, DP1
Broughan, TA1
Hermann, RE1
Castellani, WJ1
Das, KC1
Misra, HP1
Kim-Lee, MH1
Stokes, BT1
McDonald, JS1
Schmid, RA1
Yamashita, M1
Ando, K1
Tanaka, Y1
Cooper, JD1
Patterson, GA1
Leclercq, I1
Saliez, A1
Wallemacq, PE1
Horsmans, Y1
Lambotte, L1
Hyvönen, PM1
Kowolik, MJ1
Tomori, H1
Shiraishi, M1
Koga, H1
Toure, M1
Taira, K1
Higa, T1
Okuhama, Y1
Hiroyasu, S1
Muto, Y1
Ohara, F1
Sugimoto, T1
Yamamoto, N1
Ohkubo, K1
Ozaki, T1
Maeda, K1
Seki, J1
Goto, T1
Izuishi, K1
Wakabayashi, H1
Maeba, T1
Ryu, M1
Maeta, H1
Marx, G1
Leuwer, M1
Höltje, M1
Bornscheuer, A1
Herrmann, H1
Mahr, KH1
Vangerow, B1
Heine, J1
Piepenbrock, S1
Rueckoldt, H1
Lei, B1
Apaydin, AZ1
Büket, S1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Lidocaine For Neuroprotection During Cardiac Surgery[NCT00938964]550 participants (Actual)Interventional2009-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Center for Epidemiological Studies Depression Scale (CES-D)

"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-1.27
Placebo-0.89

Change in Center for Epidemiological Studies Depression Scale (CES-D)

"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine0.57
Placebo0.16

Change in Cognitive Function From Baseline

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 1 year cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement (NCT00938964)
Timeframe: 1 year after surgery

Interventionunits on a scale (Mean)
Lidocaine0.09
Placebo0.07

Change in Cognitive Function From Baseline Characterized as Continuous Cognitive Change

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 6-week cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery

Interventionunits on a scale (Mean)
Lidocaine0.07
Placebo0.07

Change in Duke Activity Status Index (DASI)

"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine6.3
Placebo6.96

Change in Duke Activity Status Index (DASI)

"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine-10.98
Placebo-11.67

Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)

The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine0.05
Placebo0.07

Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)

The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine0.05
Placebo0.04

Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)

The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine0.02
Placebo-0.02

Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)

The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine0.04
Placebo-0.01

Change in Perceived Social Support

"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine0.71
Placebo-1.16

Change in Perceived Social Support

"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine1.23
Placebo-0.49

Change in Social Activity

"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-0.20
Placebo0.03

Change in Social Activity

"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine0.95
Placebo1.59

Change in Spielberger State Anxiety Inventory (STAI)

"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-6.70
Placebo-6.39

Change in Spielberger State Anxiety Inventory (STAI)

"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine-7.12
Placebo-6.31

Change in Symptom Limitations

Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-1.39
Placebo-1.48

Change in Symptom Limitations

Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine-0.67
Placebo-0.8

Change in the Cognitive Difficulties Scale

"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-0.46
Placebo-1.02

Change in the Cognitive Difficulties Scale

"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine-3
Placebo-3.21

Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)

"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-0.15
Placebo-0.31

Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)

"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine2.46
Placebo2.1

Count of Participants With a Decline of Greater Than or Equal to One Standard Deviation in One or More of Five Cognitive Domain Scores Reported as a Dichotomous Post-operative Cognitive Deficit (POCD) Outcome

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. Each domain score is normally distributed with a mean of zero. A change score was calculated for each domain by subtracting the baseline from the 6-week score. A dichotomous outcome variable of post-operative cognitive deficit was defined as a decline of ≥1 standard deviation in 1 or more of the 5 domains. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery

InterventionParticipants (Count of Participants)
Lidocaine87
Placebo83

Change in Study 36-Item Short Form Health Survey (SF-36)

The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 1-year

,
Interventionunits on a scale (Mean)
1 year Change Work Activities1 year Change General health perception
Lidocaine-1.37-0.28
Placebo-1.42-0.43

Change in Study 36-Item Short Form Health Survey (SF-36)

The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 6-weeks

,
Interventionunits on a scale (Mean)
6-Week Change Work activities6-Week Change General health perception
Lidocaine2.71-0.004
Placebo3-0.03

Transcerebral Activation Gradient of Platelet-neutrophil Conjugates

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal

,
InterventionMean linear fluorescence intensity-MLFI (Mean)
BaselineCross-clamp removalEnd of Bypass6 hours post cross-clamp removal
Lidocaine-0.150.02-0.73-0.10
Placebo-0.43-0.73-0.400.19

Transcerebral Activation Gradients of Monocytes

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal

,
InterventionMean linear fluorescence intensity-MLFI (Mean)
BaselineCross-clamp removalEnd of Bypass6 hours post cross-clamp removal
Lidocaine-4.22-2.46-0.341.21
Placebo-0.041.832.640.54

Transcerebral Activation Gradients of Neutrophils

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removal and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal

,
InterventionMean linear fluorescence intensity-MLFI (Mean)
BaselineCross-clamp removalEnd of Bypass6 hours post cross-clamp removal
Lidocaine-2.020.560.581.04
Placebo-0.080.171.19-0.68

Transcerebral Activation Gradients of Platelets

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal

,
InterventionMean linear fluorescence intensity-MLFI (Mean)
BaselineCross-clamp removalEnd of Bypass6 hours post cross-clamp removal
Lidocaine-0.030.030.330.37
Placebo0.350.430.050.27

Reviews

2 reviews available for lidocaine and Reperfusion Injury

ArticleYear
Organ dysfunction following regional and global ischemia/reperfusion. Intervention with postconditioning and adenocaine.
    Danish medical journal, 2012, Volume: 59, Issue:8

    Topics: Adenosine; Animals; Anti-Arrhythmia Agents; Drug Combinations; Heart Arrest; Humans; Ischemia; Ische

2012
Use of systemically administered lidocaine in horses with gastrointestinal tract disease.
    Journal of the American Veterinary Medical Association, 2008, Apr-15, Volume: 232, Issue:8

    Topics: Animals; Anti-Inflammatory Agents; Gastrointestinal Diseases; Horse Diseases; Horses; Ileus; Lidocai

2008

Trials

3 trials available for lidocaine and Reperfusion Injury

ArticleYear
Effect of intravenous lidocaine on ischemia-reperfusion injury in DIEP microsurgical breast reconstruction. A prospective double-blind randomized controlled clinical trial.
    Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2021, Volume: 74, Issue:4

    Topics: Adult; Anesthetics, Local; Biomarkers; Breast Neoplasms; Double-Blind Method; Epigastric Arteries; F

2021
The effects of ketamine and lidocaine on free radical production after tourniquet-induced ischemia-reperfusion injury in adults.
    Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES, 2019, Volume: 25, Issue:2

    Topics: Adult; Biomarkers; Free Radicals; Humans; Ketamine; Lactates; Lidocaine; Lower Extremity; Reperfusio

2019
Low-dose dopexamine in patients undergoing hemihepatectomy: an evaluation of effects on reduction of hepatic dysfunction and ischaemic liver injury.
    Acta anaesthesiologica Scandinavica, 2000, Volume: 44, Issue:4

    Topics: Adult; Aged; Antithrombin III; Dopamine; Dopamine Agonists; Double-Blind Method; Female; Hemodynamic

2000

Other Studies

41 other studies available for lidocaine and Reperfusion Injury

ArticleYear
Pharmacological prevention of renal ischemia-reperfusion injury in a rat model.
    ANZ journal of surgery, 2022, Volume: 92, Issue:3

    Topics: Animals; Glutathione; Humans; Ischemia; Kidney; Lamotrigine; Lidocaine; Rats; Reperfusion Injury; Ri

2022
Adenosine, lidocaine, and magnesium for attenuating ischemia reperfusion injury from resuscitative endovascular balloon occlusion of the aorta in a porcine model.
    The journal of trauma and acute care surgery, 2022, 04-01, Volume: 92, Issue:4

    Topics: Adenosine; Animals; Aorta; Balloon Occlusion; Disease Models, Animal; Endovascular Procedures; Hemor

2022
Lidocaine relieves spinal cord ischemia-reperfusion injury via long non-coding RNA MIAT-mediated Notch1 downregulation.
    Journal of biochemistry, 2022, Mar-31, Volume: 171, Issue:4

    Topics: Animals; Down-Regulation; Lidocaine; Mice; Myocardial Infarction; Reperfusion Injury; RNA, Long Nonc

2022
Preconditioning with lidocaine and xylazine in experimental equine jejunal ischaemia.
    Equine veterinary journal, 2021, Volume: 53, Issue:1

    Topics: Animals; Horse Diseases; Horses; Ischemia; Lidocaine; Reperfusion Injury; Xylazine

2021
Effect of Intravenous Lidocaine on Inflammatory and Apoptotic Response of Ischemia-Reperfusion Injury in Pigs Undergoing Lung Resection Surgery.
    BioMed research international, 2021, Volume: 2021

    Topics: Animals; Anti-Inflammatory Agents; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Apoptosi

2021
Combatting ischemia reperfusion injury from resuscitative endovascular balloon occlusion of the aorta using adenosine, lidocaine and magnesium: A pilot study.
    The journal of trauma and acute care surgery, 2021, 12-01, Volume: 91, Issue:6

    Topics: Adenosine; Animals; Anti-Inflammatory Agents; Aorta; Balloon Occlusion; Disease Models, Animal; Drug

2021
Glycocalyx Degradation after Pulmonary Transplantation Surgery.
    European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes, 2018, Volume: 59, Issue:3-4

    Topics: Animals; Cell Adhesion; Glycocalyx; Heparitin Sulfate; Lidocaine; Lung Transplantation; Male; Neutro

2018
The effects of adenocaine (adenosine and lidocaine) on early post-resuscitation cardiac and neurological dysfunction in a porcine model of cardiac arrest.
    Resuscitation, 2013, Volume: 84, Issue:11

    Topics: Adenosine; Animals; Brain Death; Cardiopulmonary Resuscitation; Cardiovascular Agents; Coronary Angi

2013
In vitro effects of lidocaine on contractility of circular and longitudinal equine intestinal smooth muscle.
    Veterinary journal (London, England : 1997), 2013, Volume: 198, Issue:1

    Topics: Anesthetics, Local; Animals; Female; Horse Diseases; Horses; In Vitro Techniques; Isometric Contract

2013
Pulmonary function after hemorrhagic shock and resuscitation in a porcine model.
    Acta anaesthesiologica Scandinavica, 2014, Volume: 58, Issue:8

    Topics: Acute Lung Injury; Adenosine; Animals; Apoptosis; Bronchoalveolar Lavage Fluid; Cytokines; Drug Comb

2014
The Potential Effect of Epidural Anesthesia on Mesenteric Injury after Supraceliac Aortic Clamping in a Rabbit Model.
    Annals of vascular surgery, 2016, Volume: 34

    Topics: Anesthesia, Epidural; Anesthetics, Local; Animals; Aorta, Abdominal; Biomarkers; Constriction; Disea

2016
Direct intraperitoneal resuscitation with lidocaine, methylene blue and pentoxiphylline combination does not decreases inflammation after intestinal ischemia-reperfusion injury in rats.
    Acta cirurgica brasileira, 2016, Volume: 31, Issue:5

    Topics: Animals; Anti-Inflammatory Agents; Drug Combinations; Drug Synergism; Inflammation; Infusions, Paren

2016
Lidocaine Administration Controls MicroRNAs Alterations Observed After Lung Ischemia-Reperfusion Injury.
    Anesthesia and analgesia, 2016, Volume: 123, Issue:6

    Topics: Animals; Apoptosis Regulatory Proteins; Disease Models, Animal; Gene Expression Regulation; Inflamma

2016
New approach to molsidomine active metabolites coming from the results of 2 models of experimental cardiology.
    Canadian journal of physiology and pharmacology, 2017, Volume: 95, Issue:2

    Topics: Animals; Anti-Asthmatic Agents; Arrhythmias, Cardiac; Creatine Kinase; Disease Models, Animal; Hemod

2017
The impact of lidocaine on flap survival following reperfusion injury.
    The Journal of surgical research, 2011, May-15, Volume: 167, Issue:2

    Topics: Animals; Anti-Inflammatory Agents; Dose-Response Relationship, Drug; Lidocaine; Malondialdehyde; Mod

2011
In vitro effects of lidocaine on the contractility of equine jejunal smooth muscle challenged by ischaemia-reperfusion injury.
    Equine veterinary journal, 2010, Volume: 42, Issue:1

    Topics: Animals; Creatine Kinase; Female; Horses; Jejunum; Lidocaine; Male; Muscle Contraction; Muscle, Smoo

2010
[A study of the protective effects of lidocaine and nerve growth factor pretreatment on cerebral ischemia/reperfusion injury in gerbils].
    Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue, 2010, Volume: 22, Issue:4

    Topics: Animals; Apoptosis; Brain Ischemia; Disease Models, Animal; Gerbillinae; Ischemic Preconditioning; L

2010
The neuroprotective effects of lidocaine and methylprednisolone in a rat model of retinal ischemia-reperfusion injury.
    The Journal of veterinary medical science, 2012, Volume: 74, Issue:3

    Topics: Anesthetics, Local; Animals; Anti-Inflammatory Agents; Blindness; Electroretinography; Intraocular P

2012
Effects of in vivo lidocaine administration at the time of ischemia and reperfusion on in vitro contractility of equine jejunal smooth muscle.
    American journal of veterinary research, 2011, Volume: 72, Issue:11

    Topics: Anesthetics, Local; Animals; Chromatography, High Pressure Liquid; Colic; Creatine Kinase; Female; H

2011
Lidocaine and structure-related mexiletine induce similar contractility-enhancing effects in ischaemia-reperfusion injured equine intestinal smooth muscle in vitro.
    Veterinary journal (London, England : 1997), 2013, Volume: 196, Issue:3

    Topics: Animals; Creatine Kinase; Horses; Intestines; Lidocaine; Male; Mexiletine; Muscle Contraction; Muscl

2013
Free radical-induced damage in experimental peripheral nerve injection injury.
    Journal of reconstructive microsurgery, 2003, Volume: 19, Issue:6

    Topics: Analysis of Variance; Animals; Biopsy, Needle; Disease Models, Animal; Immunohistochemistry; Injury

2003
Local anesthetics worsen renal function after ischemia-reperfusion injury in rats.
    American journal of physiology. Renal physiology, 2004, Volume: 286, Issue:1

    Topics: Anesthetics, Local; Animals; Apoptosis; Blood Pressure; Bupivacaine; Gene Expression; Heart Rate; In

2004
Protective effects of lidocaine injected into the hepatoduodenal ligament on warm ischemia-reperfusion injury to the rat liver.
    Chinese medical journal, 2004, Volume: 117, Issue:2

    Topics: Animals; Duodenum; Injections; Lidocaine; Ligaments; Liver; Liver Diseases; Male; Rats; Rats, Spragu

2004
The effect of lidocaine on in vitro neutrophil and endothelial adhesion molecule expression induced by plasma obtained during tourniquet-induced ischaemia and reperfusion.
    European journal of anaesthesiology, 2004, Volume: 21, Issue:11

    Topics: Adolescent; Adult; Analysis of Variance; Anesthetics, Local; Cell Adhesion Molecules; Endothelial Ce

2004
The effect of lidocaine on neutrophil CD11b/CD18 and endothelial ICAM-1 expression and IL-1beta concentrations induced by hypoxia-reoxygenation.
    European journal of anaesthesiology, 2004, Volume: 21, Issue:12

    Topics: Analysis of Variance; Anesthetics, Local; CD11b Antigen; CD18 Antigens; Cell Hypoxia; Cells, Culture

2004
Comparison of propofol with lidocaine pretreatment versus propofol formulated with long- and medium-chain triglycerides or confounding effect of tourniquet.
    Anesthesia and analgesia, 2005, Volume: 101, Issue:1

    Topics: Anesthetics, Intravenous; Anesthetics, Local; Chemistry, Pharmaceutical; Excipients; Humans; Injecti

2005
Pre- or postinsult administration of lidocaine or thiopental attenuates cell death in rat hippocampal slice cultures caused by oxygen-glucose deprivation.
    Anesthesia and analgesia, 2005, Volume: 101, Issue:4

    Topics: Animals; Cell Death; Cell Hypoxia; Glucose; Hippocampus; Ischemia; Lidocaine; Neuroprotective Agents

2005
Effects of hypoxia/reperfusion injury on drug disposition in the rat isolated perfused liver.
    Clinical and experimental pharmacology & physiology, 2007, Volume: 34, Issue:4

    Topics: Adrenergic beta-Antagonists; Animals; Aspartate Aminotransferases; Carbon Dioxide; Carbon Radioisoto

2007
Evaluation of lidocaine treatment and risk factors for death associated with gastric dilatation and volvulus in dogs: 112 cases (1997-2005).
    Journal of the American Veterinary Medical Association, 2007, May-01, Volume: 230, Issue:9

    Topics: Animals; Breeding; Dog Diseases; Dogs; Female; Gastric Dilatation; Genetic Predisposition to Disease

2007
Protection of cellular and mitochondrial functions against liver ischemia by N-benzyl-N'-(2-hydroxy-3,4-dimethoxybenzyl)-piperazine (BHDP), a sigma1 ligand.
    European journal of pharmacology, 2008, Jan-14, Volume: 578, Issue:2-3

    Topics: Adenosine Triphosphate; Animals; Biotransformation; Cell Membrane; Cell Respiration; Cold Ischemia;

2008
Monoethylglycinexylidide formation as an independent measure of warm hepatic ischemia and reperfusion injury.
    The Journal of surgical research, 1995, Volume: 59, Issue:3

    Topics: Adenosine Triphosphate; Animals; Hot Temperature; Lidocaine; Liver; Liver Diseases; Male; Mitochondr

1995
Amelioration of postischemic reperfusion injury by antiarrhythmic drugs in isolated perfused rat lung.
    Environmental health perspectives, 1994, Volume: 102 Suppl 10

    Topics: Animals; Anti-Arrhythmia Agents; In Vitro Techniques; Ischemia; Lidocaine; Lung; Male; Organ Size; P

1994
Procaine, lidocaine, and hypothermia inhibit calcium paradox in glial cells.
    Anesthesia and analgesia, 1994, Volume: 79, Issue:4

    Topics: Analysis of Variance; Calcium; Carrier Proteins; Humans; Hypothermia; Lidocaine; Neuroglia; Procaine

1994
Lidocaine reduces reperfusion injury and neutrophil migration in canine lung allografts.
    The Annals of thoracic surgery, 1996, Volume: 61, Issue:3

    Topics: Animals; CD11 Antigens; Cell Adhesion; Chemotaxis, Leukocyte; Disease Models, Animal; Dogs; Flow Cyt

1996
The monoethylglycinexylidide test does not correctly evaluate lidocaine metabolism after ischemic liver injury in the rat.
    Hepatology (Baltimore, Md.), 1997, Volume: 26, Issue:5

    Topics: Animals; Bilirubin; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Enzymes; F

1997
Dose-dependent suppression of the neutrophil respiratory burst by lidocaine.
    Acta anaesthesiologica Scandinavica, 1998, Volume: 42, Issue:5

    Topics: Adult; Analgesics; Anesthetics, Local; Anti-Inflammatory Agents; Area Under Curve; Biocompatible Mat

1998
Protective effects of lidocaine in hepatic ischemia/reperfusion injury in vitro.
    Transplantation proceedings, 1998, Volume: 30, Issue:7

    Topics: Animals; Aspartate Aminotransferases; In Vitro Techniques; Ischemia; Lidocaine; Liver; Liver Circula

1998
Protective effect of FR168888, a new Na+/H+ exchange inhibitor, on ischemia and reperfusion-induced arrhythmia and myocardial infarction in rats: in comparison with other cardioprotective compounds.
    Japanese journal of pharmacology, 1999, Volume: 80, Issue:4

    Topics: Anesthesia; Animals; Arrhythmias, Cardiac; Benzyl Alcohol; Benzyl Alcohols; Diltiazem; Dose-Response

1999
Lidocaine-metabolizing activity after warm ischemia and reperfusion of the rat liver in vivo.
    World journal of surgery, 2000, Volume: 24, Issue:1

    Topics: Alanine Transaminase; Anesthetics, Local; Animals; Cytochrome P-450 Enzyme System; Lidocaine; Liver;

2000
Neuroprotective effect of low-dose lidocaine in a rat model of transient focal cerebral ischemia.
    Anesthesiology, 2001, Volume: 95, Issue:2

    Topics: Anesthetics, Local; Animals; Blood Gas Analysis; Body Weight; Brain Infarction; Brain Ischemia; Hemo

2001
Regional lidocaine infusion reduces postischemic spinal cord injury in rabbits.
    Texas Heart Institute journal, 2001, Volume: 28, Issue:3

    Topics: Anesthesia, Conduction; Anesthetics, Local; Animals; Infusions, Intra-Arterial; Lidocaine; Paraplegi

2001